🌙 Moonlitic
Trial Sponsor Console

Your trials — match, offer, enroll

Publish trial criteria, see the de-identified count of consented patients who match, and let Moonlitic surface your trial directly to those patients. You never see identifiers until a patient accepts your offer.

How matching works: Moonlitic queries patients' consented FHIR R4 records against your criteria. Cohort counts below 10 are suppressed (k-anonymity). SUD / genetic / mental-health codes are blocked at this layer — those patients can find your trial only through their own discovery flow with explicit Part 2 consent.
3
Active trials
68
Patients enrolled
412
Matched but not yet accepted
$87,500
Compensation budget remaining

Active trials

HER2-positive breast cancer · adjuvant therapy phase III
TRIAL-MA42-91 · Protocol IRB-MA42-2026 · NCT05887421 · Enrollment closes 2026-09-30
Active
Enrollment progress 42 / 200 enrolled (21%)
196
Matched · not yet accepted Consented patients meeting your criteria, surfaced in their portals
acl-tx: ACL-CTM-A1F4D7E209
De-identified demographics
Age 18–34:12 Age 35–49:68 Age 50–64:81 Age 65+:35 Gender (F):196 States ≥10:TX, CA, NY, IL, FL
Your criteria
Dx: C50.911 Age 40–75 Gender: female Excl. prior trastuzumab States: TX, CA, NY, IL, FL Compensation: $1,500 / patient
✓ IRB approved · expires 2027-12-31 ✓ ClinicalTrials.gov registered Contact-on-accept enabled $300,000 budget · $63,000 disbursed
CGM adherence & outcomes — phase IV observational
TRIAL-CGM21-14 · Protocol IRB-MA42-2026-CGM · NCT06014332 · Closes 2026-05-09 (5 days)
Active
Enrollment progress 187 / 500 enrolled (37%)
204
Matched · not yet accepted CGM device on file, T2DM dx, HbA1c last 90 days
acl-tx: ACL-CTM-B72E913F8C
De-identified demographics
Age 35–49:42 Age 50–64:94 Age 65+:68 Gender (F):112 Gender (M):92 States ≥10:TX, CA, NY, GA, FL
Your criteria
Dx: E11.9 Age 30–80 Active CGM device on file HbA1c last 90 days Geography: any state Compensation: $400 / patient
✓ IRB approved · expires 2027-06-30 ✓ ClinicalTrials.gov registered ⚠ Closes in 5 days $200,000 budget · $74,800 disbursed
Cardiac rehabilitation outcomes — phase IV observational
TRIAL-CR18-04 · Protocol IRB-MA42-2026-CR · paused 2026-04-22 for IRB amendment
Paused — IRB amendment
Enrollment progress 23 / 100 enrolled (23%) · paused
⚠ IRB amendment under review No new matches surfaced while paused Existing 23 enrollees: visits continue
⚖️

Sponsor query restrictions — automatically enforced

Your criteria cannot target ICD-10 prefixes F10–F19 (substance use · 42 CFR Part 2), Z14–Z15, Z80–Z84 (genetic · GINA), or be limited to F32/F33 alone (mental-health-only · Texas §611). These patients can discover your trial only through their own portal with specific Part 2 / mental-health consent. State-bucket reporting suppresses any state with fewer than 10 matched patients (k-anonymity). You never see identifiers until a patient accepts your offer in their portal.
Wired through: F05_Marketplace/clinical-trials-matcher.js · data-entitlement-engine.js (CLINICAL_TRIAL company type) · F02 Clinical Intelligence (FHIR R4 query) · F01 Consent Engine (per-patient consent gating) · F06 Payouts (compensation disbursement)

Demo data — production wires to F05_Marketplace/clinical-trials-matcher.js (commit 0b7344f).